RAPID Review of ACUTE Respiratory Distress Syndrome in Adults.


Springate C1, Martin A2, Ghosh B2, Gould H2, Rice H2, Rutherford L3, Furber A2
1Crystallise Ltd., Basildon, ESS, UK, 2Crystallise Ltd., Basildon, UK, 3LOTUC Consulting Ltd, London, UK

OBJECTIVES : To provide a rapid overview of the evidence on the epidemiology, burden, and management of ARDS, including COVID-19.

METHODS : We conducted a focused search of MEDLINE, Embase, heoro.com, clinicaltrials.gov and key HTA and regulatory sites for primary research, guidelines and HTA reports on the epidemiology, economic and humanistic burden, management, and unmet needs in ARDS. Titles and abstracts were screened and indexed to give priority to HTA and SLRs and larger more recent studies. Included studies were added to an Evidence Map and relevant data was summarised.

RESULTS : The shortlist included 485 articles, of which 113 were ongoing trial protocols. We also included 13 guidelines, 19 HTA documents, 18 RCTs, and 17 narrative reviews. ARDS affects 1 to 10% of patients in ICU and mortality rates are 20 to 30%. Risk factors include trauma, pneumonia, and sepsis. No intervention has been shown to significantly reduce mortality, and improvement in overall rates of mechanical ventilation were minimal. Survivors and caregivers have impaired quality of life. 30 to 40% of survivors, and 30% of caregivers, suffer with neuropsychiatric problems, and fewer than 50% of survivors have returned to work 12 months post-discharge. Other unmet needs include diagnosis issues, poor communication of prognosis and a lack of discussion of patient preferences. One third of ongoing trials and articles published in the last year were related to COVID-19, with interventions assessed including angiotensin II receptor blockers, stem cells, corticosteroids, and hydroxychloroquine.

CONCLUSIONS : The review highlighted the long-term burden of survivors, in terms of employment issues, psychological well-being, PTSD, as well as the negative impact on caregivers. The review also highlighted patient subgroups with differences in symptom severity, prognosis, and subsequent cost implications. The Evidence Map allows a rapid investigation of the area and, by highlighting gaps, could help guide and inform future research.

Conference/Value in Health Info

2020-11, ISPOR Europe 2020, Milan, Italy

Value in Health, Volume 23, Issue S2 (December 2020)




Epidemiology & Public Health, Health Service Delivery & Process of Care, Patient-Centered Research

Topic Subcategory

Disease Management, Patient-reported Outcomes & Quality of Life Outcomes, Treatment Patterns and Guidelines


Respiratory-Related Disorders

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now